
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016
- Volume 12
- Issue 2
Onyx Scientific Announces Facility Expansion
Planned expansion at Onyx Scientific add laboratories, GMP suites, and storage space.
Onyx Scientific, a UK-based contract research organization and and small-scale API manufacturer, has announced an investment in an additional site located adjacent to its existing facility in North-East England to increase its laboratory facilities, GMP suites, and storage of GMP materials. In addition, the company has recruited several more chemists to support clients’ pre-clinical, development, and early-stage API manufacturing projects.
In 2015, the company grew its GMP space following an increase in demand for its small-scale API manufacturing services, according to a Jan. 28, 2016 press statement.
Established in 2000, the company provides clients with the production of API in up to 50 L–100 L equipment under current GMP regulations, and also offers earlier stage custom synthesis, lead optimization, and analytical services.
Source:
Articles in this issue
almost 10 years ago
Is Consolidation Good for Pharma?almost 10 years ago
Parenteral Packagers Focus on Security and Supply-Chain Transparencyalmost 10 years ago
Nanoparticles Demonstrate Potential for Small-Molecule Pharmaceuticalsalmost 10 years ago
Hermes Pharma Adds Hot Melt Coating Capabilityalmost 10 years ago
Novasep Adds Small-Scale Manufacturing Capability to US Facilityalmost 10 years ago
Vetter Completes Development and IT Facilityalmost 10 years ago
Adents, Siemens Team on Serialization Solutionalmost 10 years ago
GS1 US Expands Advisory Services Program to Address Industry Challengesalmost 10 years ago
FDA’s CDER Previews 2016 Guidance Agendaalmost 10 years ago
SGS Life Sciences Expands Chemistry and Microbiology Testing ServicesNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





